Pharmicell Co., Ltd.

KSE 005690.KS

Pharmicell Co., Ltd. Operating Income Margin for the year ending December 31, 2023: 1.69%

Pharmicell Co., Ltd. Operating Income Margin is 1.69% for the year ending December 31, 2023, a -88.53% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Pharmicell Co., Ltd. Operating Income Margin for the year ending December 31, 2022 was 14.74%, a -1.40% change year over year.
Pharmicell Co., Ltd. Operating Income Margin for the year ending December 31, 2021 was 14.95%, a -21.95% change year over year.
Pharmicell Co., Ltd. Operating Income Margin for the year ending December 31, 2020 was 19.16%, a 216.95% change year over year.
Pharmicell Co., Ltd. Operating Income Margin for the year ending December 31, 2019 was 6.05%, a 558.74% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

KSE: 005690.KS

Pharmicell Co., Ltd.

CEO	Mr. Hyun-Soo Kim
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	Ssangbong Building
Employees	136
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Composite Materials Non-Alcoholic Beverages Petrochemicals Pharmaceuticals Plastics

Description

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years